We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
Read MoreHide Full Article
PerkinElmer, Inc. is well-poised for growth, courtesy of a robust product portfolio and impressive margin expansion. However, forex remains a concern.
Shares of this currently Zacks Rank #3 (Hold) company have gained 17.4% compared with the industry’s growth of 15.7% over the past year. The S&P 500 Index has rallied 19.2% in the same time frame.
PerkinElmer — with a market capitalization of $22.31 billion — offers scientific instruments, consumables and services to pharmaceutical, biomedical, environmental testing, chemical and general industrial markets worldwide. It anticipates earnings to improve 44.8% over the next five years. The company has a trailing four-quarter earnings surprise of 21.5%, on average.
Key Catalysts
PerkinElmer delivers a comprehensive suite of scientific informatics and software solutions to aggregate data into actionable insights in an automated and scalable way.
Per management, the company spent an incremental $25 million on people and digital capabilities and invested more than $200 million in R&D to continuously develop a robust pipeline of new products across a full array of technologies.
COVID-related products and services contributed $300 million in the third quarter of 2021, primarily driven by the company’s core products and COVID-related lab services. Per management, the company’s COVID and non-COVID revenue performance surpassed expectations with double-digit growth in its Discovery & Analytical Solutions and Diagnostics segments.
Image Source: Zacks Investment Research
With respect to COVID-related product launches and approvals, in October 2021, EUROIMMUN, a PerkinElmer company, announced that it has received the FDA’s Emergency Use Authorization (EUA) for its Anti-SARS-CoV-2 S1 Curve ELISA (IgG). This assay enables the qualitative and semi-quantitative detection of IgG antibodies produced against the SARS-CoV-2 S1 antigen in human serum and plasma. In the same month, PerkinElmer announced that it has received EUA from the FDA for the PKamp Respiratory SARS-CoV-2-RT-PCR Panel 1 assay.
The company’s gross and operating margin continues to improve on the back of productivity initiatives and volume leverage. The product introductions are anticipated to enhance the product mix, increasing the gross margin. This, coupled with stringent cost control, will continue to drive the operating margin in the near term.
In the third quarter of 2021, adjusted gross profit amounted to $673.5 million, up 23.7% year over year. Adjusted gross margin, as a percentage of revenues, was 57.7%, up 120 basis points (bps) year over year. Adjusted operating income was $358.9 million, which climbed 17.9% from the year-ago quarter. The company’s adjusted operating margin remained robust at 31%.
Factor Hurting the Stock
Growing exposure to the international markets makes the company susceptible to the risk of adverse foreign exchange volatility. The unfavorable fluctuations in currency exchange rates can affect PerkinElmer’s international sales.
Estimate Trend
PerkinElmer has been witnessing an upward estimate revision trend for 2021. In the past 60 days, the Zacks Consensus Estimate for its earnings moved north by 1.3% to $10.97.
The Zacks Consensus Estimate for fourth-quarter 2021 revenues is pegged at $1.30 billion, suggesting a decline of 3.9% from the year-ago reported number.
Stocks to Consider
Some better-ranked stocks in the broader medical space include AMN Healthcare Services, Inc. (AMN - Free Report) , Henry Schein, Inc. (HSIC - Free Report) and Laboratory Corporation of America Holdings (LH - Free Report) .
AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 19.5%. The company currently sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare’s long-term earnings growth rate is estimated at 16.2%. The company’s earnings yield of 5.5% compares favorably with the industry’s 0.8%.
Henry Schein beat earnings estimates in each of the trailing four quarters, the average surprise being 21.9%. The company currently carries a Zacks Rank #2 (Buy).
Henry Schein’s long-term earnings growth rate is estimated at 11.8%. The company’s earnings yield of 5.9% compares favorably with the industry’s 4.1%.
Laboratory Corporation surpassed earnings estimates in each of the trailing four quarters, the average surprise being 25.7%. The company currently sports a Zacks Rank #1.
Laboratory Corporation’s long-term earnings growth rate is estimated at 10.6%. The company’s earnings yield of 9.4% compares favorably with the industry’s 3.4%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
PerkinElmer, Inc. is well-poised for growth, courtesy of a robust product portfolio and impressive margin expansion. However, forex remains a concern.
Shares of this currently Zacks Rank #3 (Hold) company have gained 17.4% compared with the industry’s growth of 15.7% over the past year. The S&P 500 Index has rallied 19.2% in the same time frame.
PerkinElmer — with a market capitalization of $22.31 billion — offers scientific instruments, consumables and services to pharmaceutical, biomedical, environmental testing, chemical and general industrial markets worldwide. It anticipates earnings to improve 44.8% over the next five years. The company has a trailing four-quarter earnings surprise of 21.5%, on average.
Key Catalysts
PerkinElmer delivers a comprehensive suite of scientific informatics and software solutions to aggregate data into actionable insights in an automated and scalable way.
Per management, the company spent an incremental $25 million on people and digital capabilities and invested more than $200 million in R&D to continuously develop a robust pipeline of new products across a full array of technologies.
COVID-related products and services contributed $300 million in the third quarter of 2021, primarily driven by the company’s core products and COVID-related lab services. Per management, the company’s COVID and non-COVID revenue performance surpassed expectations with double-digit growth in its Discovery & Analytical Solutions and Diagnostics segments.
With respect to COVID-related product launches and approvals, in October 2021, EUROIMMUN, a PerkinElmer company, announced that it has received the FDA’s Emergency Use Authorization (EUA) for its Anti-SARS-CoV-2 S1 Curve ELISA (IgG). This assay enables the qualitative and semi-quantitative detection of IgG antibodies produced against the SARS-CoV-2 S1 antigen in human serum and plasma. In the same month, PerkinElmer announced that it has received EUA from the FDA for the PKamp Respiratory SARS-CoV-2-RT-PCR Panel 1 assay.
The company’s gross and operating margin continues to improve on the back of productivity initiatives and volume leverage. The product introductions are anticipated to enhance the product mix, increasing the gross margin. This, coupled with stringent cost control, will continue to drive the operating margin in the near term.
In the third quarter of 2021, adjusted gross profit amounted to $673.5 million, up 23.7% year over year. Adjusted gross margin, as a percentage of revenues, was 57.7%, up 120 basis points (bps) year over year. Adjusted operating income was $358.9 million, which climbed 17.9% from the year-ago quarter. The company’s adjusted operating margin remained robust at 31%.
Factor Hurting the Stock
Growing exposure to the international markets makes the company susceptible to the risk of adverse foreign exchange volatility. The unfavorable fluctuations in currency exchange rates can affect PerkinElmer’s international sales.
Estimate Trend
PerkinElmer has been witnessing an upward estimate revision trend for 2021. In the past 60 days, the Zacks Consensus Estimate for its earnings moved north by 1.3% to $10.97.
The Zacks Consensus Estimate for fourth-quarter 2021 revenues is pegged at $1.30 billion, suggesting a decline of 3.9% from the year-ago reported number.
Stocks to Consider
Some better-ranked stocks in the broader medical space include AMN Healthcare Services, Inc. (AMN - Free Report) , Henry Schein, Inc. (HSIC - Free Report) and Laboratory Corporation of America Holdings (LH - Free Report) .
AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 19.5%. The company currently sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare’s long-term earnings growth rate is estimated at 16.2%. The company’s earnings yield of 5.5% compares favorably with the industry’s 0.8%.
Henry Schein beat earnings estimates in each of the trailing four quarters, the average surprise being 21.9%. The company currently carries a Zacks Rank #2 (Buy).
Henry Schein’s long-term earnings growth rate is estimated at 11.8%. The company’s earnings yield of 5.9% compares favorably with the industry’s 4.1%.
Laboratory Corporation surpassed earnings estimates in each of the trailing four quarters, the average surprise being 25.7%. The company currently sports a Zacks Rank #1.
Laboratory Corporation’s long-term earnings growth rate is estimated at 10.6%. The company’s earnings yield of 9.4% compares favorably with the industry’s 3.4%.